Leerink Partnrs Has Pessimistic View of VRTX Q4 Earnings

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) – Equities researchers at Leerink Partnrs decreased their Q4 2025 earnings per share estimates for shares of Vertex Pharmaceuticals in a research note issued to investors on Thursday, September 25th. Leerink Partnrs analyst D. Risinger now anticipates that the pharmaceutical company will post earnings per share of $4.67 for the quarter, down from their previous estimate of $4.70. Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for Vertex Pharmaceuticals’ current full-year earnings is $15.63 per share.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its earnings results on Monday, August 4th. The pharmaceutical company reported $4.52 earnings per share for the quarter, topping the consensus estimate of $4.24 by $0.28. The business had revenue of $2.94 billion for the quarter, compared to analyst estimates of $2.90 billion. Vertex Pharmaceuticals had a return on equity of 23.91% and a net margin of 31.86%.The business’s quarterly revenue was up 11.3% on a year-over-year basis. During the same period last year, the company posted ($12.83) EPS. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS.

Several other brokerages have also weighed in on VRTX. Evercore ISI cut their target price on Vertex Pharmaceuticals from $510.00 to $475.00 and set an “outperform” rating on the stock in a research report on Thursday, September 11th. Raymond James Financial started coverage on Vertex Pharmaceuticals in a report on Tuesday, September 2nd. They issued a “market perform” rating for the company. UBS Group set a $553.00 price target on Vertex Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, August 5th. Leerink Partners upgraded Vertex Pharmaceuticals from a “market perform” rating to an “outperform” rating and lowered their price target for the company from $458.00 to $456.00 in a report on Thursday. Finally, Scotiabank lowered their price target on Vertex Pharmaceuticals from $442.00 to $438.00 and set a “sector perform” rating for the company in a report on Tuesday, August 5th. Two analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and eleven have given a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $493.81.

Vertex Pharmaceuticals Trading Up 1.0%

Shares of VRTX opened at $385.73 on Friday. The firm has a market capitalization of $98.90 billion, a P/E ratio of 27.57 and a beta of 0.44. The stock’s fifty day simple moving average is $406.00 and its 200 day simple moving average is $446.60. Vertex Pharmaceuticals has a twelve month low of $362.50 and a twelve month high of $519.88.

Insider Activity

In other Vertex Pharmaceuticals news, Director Bruce I. Sachs bought 5,000 shares of the company’s stock in a transaction dated Wednesday, August 6th. The shares were acquired at an average cost of $389.68 per share, with a total value of $1,948,400.00. Following the completion of the transaction, the director owned 45,000 shares in the company, valued at $17,535,600. The trade was a 12.50% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.20% of the company’s stock.

Institutional Trading of Vertex Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of VRTX. Norges Bank purchased a new stake in shares of Vertex Pharmaceuticals during the second quarter worth about $1,593,974,000. GAMMA Investing LLC increased its position in shares of Vertex Pharmaceuticals by 60,572.3% during the first quarter. GAMMA Investing LLC now owns 2,425,070 shares of the pharmaceutical company’s stock worth $1,175,722,000 after acquiring an additional 2,421,073 shares during the last quarter. Price T Rowe Associates Inc. MD increased its position in shares of Vertex Pharmaceuticals by 72.5% during the first quarter. Price T Rowe Associates Inc. MD now owns 2,917,227 shares of the pharmaceutical company’s stock worth $1,414,331,000 after acquiring an additional 1,226,527 shares during the last quarter. Jennison Associates LLC increased its position in shares of Vertex Pharmaceuticals by 21.5% during the second quarter. Jennison Associates LLC now owns 6,151,505 shares of the pharmaceutical company’s stock worth $2,738,650,000 after acquiring an additional 1,089,063 shares during the last quarter. Finally, Nuveen LLC purchased a new stake in shares of Vertex Pharmaceuticals during the first quarter worth about $484,053,000. 90.96% of the stock is owned by hedge funds and other institutional investors.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.